ALPN NASDAQ
Seattle, WA 98102
US
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Peetz Christopher | D-Return | 7,650 | $7.91 | 2024-05-20 |
| Peetz Christopher | D-Return | 17,500 | $19.00 | 2024-05-20 |
| Peetz Christopher | D-Return | 10,000 | $7.43 | 2024-05-20 |
| Peetz Christopher | D-Return | 10,000 | $13.89 | 2024-05-20 |
| Peetz Christopher | D-Return | 7,650 | $13.45 | 2024-05-20 |